Overview

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

Status:
Completed
Trial end date:
2018-01-17
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
Phase:
Phase 2
Details
Lead Sponsor:
Apellis Pharmaceuticals, Inc.